Drug Profile
Besifovir - IlDong Pharmaceuticals/LG Chem
Alternative Names: ANA-380; Besifovir dipivoxil - IlDong Pharmaceuticals/LG Chem; Besifovir Dipivoxil Maleate - IlDong Pharmaceuticals/LG Chem; Besivo; LB-80380Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer Ildong Pharmaceutical; LG Life Sciences
- Class Antivirals; Hypoxanthines; Phosphonic acids; Purine nucleotides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 29 Jul 2021 IlDong Pharmaceutical initiates a phase I trial (In volunteers and participants with renal failure) in February 2020 (PO) (NCT04249908)
- 31 Jan 2020 IlDong Pharmaceutical plans a phase I trial (In volunteers and participants with renal failure) in February 2020 (PO) (NCT04249908)
- 13 Jan 2019 Launched for Hepatitis B (Monotherapy, Treatment-resistant) in South Korea (PO) (NCT03885778) before January 2019